Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis

NCT05544591 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

93

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis, Atopic

Interventions

DRUG: 611 Q2W
DRUG: 611 Q4W
DRUG: Matching placebo

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.